outcomes

Scope of the problem
Obesity represents a condition of excessive adipose tissue with its currently accepted definition based on body mass index (BMI) calculated as follows: weight/(height) 2 , where weight is measured in kilograms and height in meters. The National Heart, Lung, and Blood Institute and the World Health Organization have reached consensus that overweight reflects a BMI of 425 kg/m 2 and obesity is defined as a BMI 430 kg/m 2 ).
1,2 Using this definition, the incidence of obesity in the developed world continues to increase annually despite a recent trend toward decreased fat intake and a modest decrement in caloric intake. [3] [4] [5] In the United States among adults aged 20-74 years surveyed in 1999-2000, 27 .7% of men and 34% of women are obese (BMI 430 kg/m 2 ) and 3.1% of men and 6.3% of women are extremely obese (BMI 440 kg/m 2 ) 5 . Despite the high frequency of obesity in the population, the impact of obesity in the context of high-dose chemotherapy (HDC) with stem cell rescue or hematopoietic cell transplant (HCT) has been studied only minimally in adults and even less in children. Owing to the paucity of data in children, this review will focus on outcomes in adult patients.
In caring for obese cancer patients in the context of HCT, the following questions arise:
(1) How does one appropriately dose intensive chemotherapy in the obese patient? What is known about the pharmacokinetics of chemotherapy in obese patients? (2) Are chemotherapy-related toxicities different in obese compared to non-obese patients? (3) Are endpoints such as treatment-related mortality, overall survival (OS), or relapse rates equivalent or different for obese patients undergoing HCT?
This review will discuss the existing literature, some of which are conflicting, and will also address future directions for research in this area.
Chemotherapy pharmacokinetics issues in the obese patient
Most chemotherapeutic agents fit the two-compartment open pharmacokinetics model. In this model, a quantity of drug (D) administered intravenously is then distributed throughout the body during the distribution phase with a concentration half-life termed t 1/2 a. This phase is rapid for most chemotherapeutics. Immediately following the distribution phase is the terminal elimination phase, designated t 1/2 b. Assuming first-order, linear kinetics, t 1/2 b is related to the apparent volume of distribution (V D ) and inversely to the drug clearance (CL) ( Table 1 ). The apparent volume of distribution relates the observed plasma concentration to the quantity of drug present in the body and therefore, under certain circumstances, can exceed the actual body volume, such as when drug distributes preferentially to adipose tissue.
Unfortunately, in the setting of HDC administration, such a simplistic model system may fail for diverse reasons: (1) the elimination kinetics may be non-linear at high doses, such as when metabolizing enzymes become saturated or necessary substrates become depleted, particularly in glucuronidation; (2) protein binding may alter the volume of distribution and therefore drug clearance, or (3) the physicochemical features of a drug may lead to high adipose distribution, again altering the volume of distribution and clearance. Thus, pharmacokinetic modeling in HDC remains challenging and generally suboptimal (Table 2) .
Obesity may also alter the pharmacokinetics of chemotherapy. Given the altered percentage of adipose tissue in the peripheral compartment of the two-compartment pharmacokinetic model, central vs peripheral compartment drug distribution is potentially perturbed. Other possible mechanisms for disturbed pharmacokinetics in obese patients include altered relative distribution of blood flow to liver and kidneys, increased plasma protein volume with concomitant increased drug binding, and decreased CL secondary to hepatic dysfunction from fatty deposition ( Table 2 ).
Chemotherapy dosing in obese patients
With the complexity of predicting pharmacokinetics in this setting and the paucity of data, it is hardly surprising then that no standard approach to chemotherapy dosing has been universally adopted. A recent international survey of chemotherapy dosing schemes among transplant centers revealed that there is no consensus regarding appropriate dose adjustment for obese patients. 6 In all, 24% of centers surveyed used actual weight without modification, whereas 15% used ideal weight only; the remainder used various dose adjustment schemes with some percentage of weight above ideal added in varying proportions to ideal weight to calculate a corrected weight for dosing. The resulting difference in dosing was striking and could potentially exceed 100%. Excessive doses of chemotherapy represent a risk for increased toxicity. For example, the incidence of hepatic veno-occlusive disease/hepatic sinusoidal obstruction syndrome appears to strongly correlate with areaunder-the-curve (AUC) exposure to oral busulfan. 7, 8 Conversely, underdosing chemotherapy represents an efficacy risk. Accordingly, busulfan given orally with plasma concentrations at steady state less than 900 ng/ml correlated with increased risk of relapse in chronic myeloid leukemia (CML) patients undergoing allogeneic HCT. 9 Low steady state busulfan concentrations were also demonstrated to result in increased incidence of graft rejection. 10 Both over-and underdosing can therefore detrimentally affect outcome. Our current practice is to calculate the dose of intensive chemotherapy based on an adjusted weight, where adjusted weight is ideal weight, plus 25% of the difference between actual and ideal weight. This formula derives from our acute myeloid leukemia (AML) HCT experience utilizing busulfan at 16 mg/kg and etoposide at 60 mg/kg during the era of purged marrow. Excessive skin and GI toxicity was observed using 50% of the difference of ideal and actual added to ideal weight for patients greater than 130% of ideal weight. This led to the empiric decision to use ideal weight plus 25% of the difference between ideal and actual weight (C Linker, personal communication).
Pharmacokinetics of standard dose chemotherapy in obesity
Some investigators have attempted to characterize the pharmacokinetics of standard dose chemotherapeutics in the obese patient. Postulating that the lipophilic characteristics of drugs may impact on drug disposition in obese patients, Abernathy et al 11 in the early 1980s prospectively assayed the pharmacokinetics of the hydrophilic drug antipyrine and the lipophilic drug diazepam to elucidate the impact of apparent volume of distribution on clearance. In that work, obese patients demonstrated increased t 1/2 b of antipyrine attributable to both modest increases in the volume of distribution and to diminished clearance. For diazepam, increased t 1/2 b was also observed, but this was nearly entirely accounted for by a markedly increased V D to adipose tissue (91 vs 292 l). Moreover, in a study examining the impact of obesity on standard dose doxorubicin, AUC exposure (2209 vs 1190 ng h/ml) and t 1/2 b (20.4 h vs 13.0 h) were significantly prolonged in obese patients. 12 In this work, however, the apparent V D was equivalent between nonobese and obese patients, indicating that the prolongation t 1/2 b was attributable to decreased doxorubicin clearance. The pharmacokinetics of ifosphamide were explored in lung cancer patients in which four of 16 patients were obese, defined as greater than 20% above ideal body weight (IBW). 13 The t 1/2 b was prolonged in the obese group (6.36 vs 4.95 h, Po0.05) because of an increased apparent V D rather than decreased clearance, suggesting increased drug distribution to adipose tissue. In women with breast cancer receiving cyclophosphamide, however, a pharmacokinetic study showed that obese women had prolonged t 1/2 b and decreased clearance compared to non-obese women.
14 The reason for observed pharmacokinetic differences between ifosfamide and cyclophosphamide, otherwise chemically similar chemotherapeutic agents, is not at all clear. The t 1/2 b was consistently prolonged in these studies but the mechanism, either decreased clearance or increased apparent volume of distribution, appears to be drug dependent (Table 3) . Table 1 Pharmacokinetic relations
Pharmacokinetics of HDC in obese patients
Even fewer studies have addressed the question of HDC in obese patients. Some drugs administered at high doses may be cleared by nonlinear kinetics, further complicating the prediction of pharmacodynamics. In nonobese individuals receiving high-dose busulfan, Hassan et al 15 measured busulfan levels in five subjects to explore intrapatient differences in clearance between the first and final doses of busulfan. The t 1/2 b dropped from 3.4 h after the first dose to 2.3 h following the final dose, suggesting that busulfan may induce its own metabolism. In a study of busulfan pharmacokinetics conducted at the Fred Hutchinson Cancer Research Center by Gibbs et al, 16 the oral clearance of busulfan in 279 patients was ascertained. Busulfan dosing was adjusted for all patients based on initial busulfan dose plasma levels. Busulfan clearance was increased by 16.2% in obese patients (defined as BMI 27-35 kg/m 2 ). Of note, however, is the finding of even greater variability between patients with CML compared to those with non-Hodgkin's lymphoma (NHL) with the NHL patients showing 36% decreased clearance. The explanation for such a difference based on diagnosis is not obvious but clearly overshadows any impact of obesity on busulfan clearance.
The pattern emerging from these investigations, the Gibbs study notwithstanding, is that obese patients receiving chemotherapy often experience a prolonged t 1/2 b relative to nonobese patients through diminished clearance and/or increased apparent V D . Further investigations attempting to address the issue specifically of HDC in the obese are sorely needed to clarify the optimal dosing scheme in this group of patients.
Chemotherapy pharmacodynamics in obese patients
Toxicity and relapse rates are the two most critical pharmacodynamic parameters of chemotherapy. It is frequently assumed that these two parameters are inversely related: that is, diminished toxicity implies increased rate of relapse and vice versa. Whether this assumption is valid in the context of obesity is unclear. Further complicating this issue in the obese patient is the common use of chemotherapy dose adjustment schemes. Aiming to clarify the relation between dose intensity and toxicity in obese patients, Poikonen et al 17 reviewed outcomes for women receiving CMF for breast cancer and found higher leukocyte nadirs in obese patients despite dosing at actual weight, suggesting mild underdosing. In CALGB study 8541, breast cancer patients received cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) based on actual weight. No differences in toxicity outcomes were seen, although women who received dose reductions on the first cycle, presumably dose adjustment for weight, showed an inferior failure-free survival. 18 These investigations showed that obese patients generally tolerated standard chemotherapy doses based on actual weight without experiencing excessive toxicity and also implied that some obese patients may be underdosed. This is distinctly different from the conclusions one would draw from the pharmacokinetic data revealing prolonged t 1/2 b and therefore higher AUC exposure.
Bastarrachea et al 19 at the MD Anderson Cancer Center reviewed disease-free survival in 735 node-positive breast cancer patients undergoing adjuvant CAF chemotherapy. Patients were classified as obese if they were 4120% of IBW. A proportional-hazards regression model indicated that the relative risk of disease recurrence in obese patients was 1.33 (confidence interval 1.05-1.68, P ¼ 0.02) with 54% of nonobese patients remaining disease-free vs 40% of obese patients. This study, however, could have been confounded by dose intensity, although the authors cite a previous paper 20 finding no differences in dose intensity among these patients. (For a thought-provoking review of potential bias in assessment of dose intensity, the reader is referred to commentary by Redmond et al.) 21 Caution must be exercised in interpretation of relapse rates in studies of breast cancer as the impact of endogenous estrogen production in adipose tissue promoting disease recurrence may be a potential confounder causing higher relapse in obese women unrelated to chemotherapy dosing.
Outcomes in obese patients undergoing autologous HCT
We reviewed 63 AML patients treated with autologous HCT using autologous stem cells and a dose adjustment scheme using ideal weight plus 25% of the difference between ideal and actual weight; 22 13 patients (20.6%) were at or above 130% of IBW. These patients were compared to 19 patients at 97-103% of IBW. Chemotherapy doses of high-dose busulfan and etoposide were adjusted as described above. Significantly more days of grade 2 or worse mucositis occurred in the nonobese group (8.1 days) compared to the obese group (4.6 days) (P ¼ 0.015), and a significant difference in peak alkaline phosphatase levels with a lower peak in the obese group (105.3 vs 171.1 U/l; P ¼ 0.05) was noted. Thus, the incidence of toxicity among the obese patient group was significantly less than the nonobese group. We concluded that obese patients were potentially underdosed, at least in part because of our dose adjustment scheme; no conclusions regarding relapse rates could be ascertained because of low numbers.
Meloni et al 23 recently reported in this journal the outcomes of obese patients treated for AML by autografting using actual weight for chemotherapy dosing. In that series of 54 patients, nine were classified as obese based on a BMI of greater than 27.8 kg/m 2 for men and 27.3 kg/m 2 for women. Despite small numbers, statistically significant differences in OS and disease-free survival were observed at a median follow-up of 76.5 months (Table 4) . Conversely, no differences were observed in the underweight group. There was a marked difference in toxic deaths with 33% (three of nine patients) treatment-related mortality among the obese group and 8% among the nonobese group. The authors concluded that dose adjustment for obesity is important to avoid excessive toxicity. Once again, the numbers of obese patients were too low to assess differences in relapse rates. Tarella et al 24 studied outcomes in 121 patients undergoing autologous HCT for NHL, 28 with a BMI greater than 28 kg/m 2 . Chemotherapy doses were based on actual weight without adjustment except in six patients with a BMI of X32 kg/m 2 . Treatment-related mortality was not different between the obese and non-obese groups; in fact, the obese group once again trended toward less toxicity with fewer transfusions and a lower incidence and duration of fever. However, with a median follow-up of 3 years, OS and event-free survival of the obese group were markedly inferior to the nonobese group (38 and 23% projected at 5 years vs 65 and 55%, respectively; Po0.002) ( Table 4) . Obesity constituted a significant risk for death with a relative risk of 2.9 (P ¼ 0.005), presumably related to relapse. Interestingly, it appears that the obese patients in this study may have been underdosed compared to nonobese patients based on the observations of higher relapse rates and lower toxicity, despite the lack of a dose adjustment scheme for 22 of 28 obese patients.
Reporting in 1999, the Stanford group examined outcome in 473 consecutive patients undergoing HCT for various hematologic malignancies with chemotherapy dose adjustments for obesity. 25 The patients were separated by the relation of their admission BMI to an age-adjusted BMI expressed as a percentage: 70-79% (n ¼ 17), 80-99% (n ¼ 166), 100-119% (n ¼ 186: reference group), 120-139% (n ¼ 72), 140-199% (n ¼ 32). A statistically significantly higher rate of 5-year estimated nonrelapse mortality was noted in patients whose BMI were 70-79% (18%) and 120-139% (24%) compared to the 100-119% group (13%).
Projected relapse rates, at 5 years, however, appeared relatively similar among all weight groups (Table 4) . Thus, dose adjustment appeared not to increase relapse rates, but treatment-related mortality was substantially higher in the obese groups than in the nonobese. This suggests that perhaps the dose adjustment scheme may have still led to overdosage for some obese patients.
Outcomes for obese patients undergoing allogeneic HCT Obese patients have also been shown to experience a higher rate of mortality in the setting of allogeneic HCT. Fleming et al 26 reported results of a single-institution case-control study in 76 obese adults (greater than 20% above IBW) vs 166 nonobese adult patients undergoing allogeneic stem cell transplant patients. Nonobese adult patients had an OS of 30% at a median follow-up of 296 days, while obese patients had an OS of 16% at 120 days of median follow-up (P ¼ 0.003) ( Table 5 ). Of note, there was a trend toward relapsed AML patients in the obese group (16% in the nonobese group, 25% in the obese group), a group with a poor prognosis, although the relapse rates were similar between obese and nonobese patients. No information regarding year of transplant was provided for the two groups, another factor that could impact on survival. Of note, there was no difference in OS between obese and nonobese children.
Deeg (Table 5 ). However, also at FHCRC, Hansen et al 28 reported outcome data from the Seattle experience in unrelated donor HCT for chronic phase CML 28 ( Table 5 ). The body weight index (actual divided by ideal weight) proved to be a mortality risk factor in multivariate analysis with a relative risk of 1.6 (confidence interval 1.2-2.2, P ¼ 0.001). From these diverging conclusions, it could be postulated that in a relatively favorable group such as chronic phase CML patients, obesity is an adverse factor, but when higher risk diseases are treated, obesity drops in significance.
Conclusions
Obesity appeared to adversely affect outcome in patients undergoing hematopoietic cell transplantation, although the causes for these observations remain understudied. Some reports suggest a higher treatment-related mortality, while others show only higher relapse rates, with the inconsistencies among studies perhaps a result of variable dosing schemes and consequent under-or overdosing.
Other studies, however, have shown no significant differences in relapse or toxicity, making definitive conclusions impossible because of the lack of comparability between protocols.
With respect to appropriate chemotherapy dosing, no optimal approach to adjustment is clear from the literature. There remains a paucity of information addressing the pharmacokinetics of HDC in the obese. However, the available body of work suggests that obese patients experience significant alterations in the clearance and apparent volume of distribution. Prospective studies examining the pharmacokinetics of HDC are needed to help settle some of these issues. Clearly, however, pharmacokinetic results obtained for one drug will not necessarily be applicable to all agents. We are currently planning a trial exploring the pharmacokinetics and toxicity of etoposide and busulfan in obese compared to nonobese patients to begin to address these issues.
Other factors potentially impacting on outcomes include weight limits at some institutions, either officially stated in protocols or based on patient selection prior to enrollment. Total body irradiation in the context of obesity must also be considered in assessments of preparative regimen toxicity. Adjustment of beam energy is used to insure adequate penetration of radiation to achieve the desired tissue dose. There may be less variability in radiation dose achieved compared to chemotherapy, although this area remains underexplored as well.
Finally, and perhaps most importantly, outcomes of survival and relapse in the obese population suggest that obese patients fare worse than their nonobese counterparts. This is not a uniform conclusion, however, and as was seen in a single institution (FHCRC), the importance of obesity as an adverse prognostic factor may vary depending on disease, type of transplant, regimen, and dose adjustments.
Future directions
An effort is currently underway using the substantial information resources of the International Blood and Marrow Transplant Registry (IBMTR) to retrospectively examine outcomes with respect to toxicity and relapse to confirm or refute the sometimes conflicting observations to date. While there are limitations to this approach, important trends or differences may be elucidated, leading to well-designed prospective studies to further clarify the impact of obesity on outcomes in HCT.
